This project, through training the next generation of biomedical researchers, aims to create and develop in Australia the skills and technology to enable early benefit from the transformative impacts that cell/organ-on-achip technology will have on the medtech/pharma industries. Advancing ineffective medicines into clinical trial costs vast sums of money and lost opportunities, as does using medicines in patients without benefit. Combining microfluidics-based/real-time technologies with personalised medicine should allow us to provide growth opportunities through improved screening of potential therapeutics, and use an individual patient’s cellular and molecular research findings to enable personalised diagnostic and therapeutic decisions.
|Effective start/end date||11/05/18 → 30/06/23|
- The University of Melbourne: AUD11,606.00
- SMR Automotive Australia Pty Ltd: AUD30,000.00
- Commonwealth Scientific and Industrial Research Organisation: AUD45,000.00
- Trajan Scientific and Medical: AUD35,000.00
- Monash University – Internal Faculty Contribution